ArticleInternational urology and nephrology2026
Effect of bio-platelet rich fibrin as an adjuvant covering did not decrease the incidence of post-operative complications after urethroplasty in proximal hypospadias.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on the methodological description of platelet-rich fibrin in Siregar et al. (2025).International urology and nephrology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUrethrocutaneous fistula (UCF) is the most frequent complication after urethroplasty for proximal hypospadias, with reported rates up to 30%. Bio-Platelet Rich Fibrin (Bio-PRF), a novel autologous biomaterial enriched with growth factors, is hypothesized to enhance wound healing and reduce fistula formation when applied as an intermediate layer during urethral reconstruction.
methodsThis prospective study involved patients with proximal hypospadias undergoing urethroplasty at Hasan Sadikin General Hospital, Bandung, from September 2023 to December 2024. Subjects were divided into Bio-PRF group or control group (no Bio-PRF). The primary outcome was the incidence of UCF observed on 1st, 3rd, and 6th months. Baseline characteristics and outcome data were analyzed using the independent T test or Mann-Whitney U test, and chi-square test.
resultsA total of 36 patients were enrolled (18 in each group). Baseline characteristics, including age, hypospadias subtype, glans width, urethral plate dimensions, and laboratory parameters (hematologic, coagulation profiles, and albumin) were comparable. UCF incidence was higher in the Bio-PRF group (56.6% at 6th month) compared to controls though not statistically significant (p > 0.05). There was no significant difference in other post-operative complication rate and operative time between both groups.
conclusionBio-PRF application did not significantly reduce UCF rates and other complications after proximal hypospadias urethroplasty. Further studies are warranted to clarify the clinical value of Bio-PRF in pediatric reconstructive urology.
Indexed as
Identifiers
41372606What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.